Sign in

CIK 0001395937 · Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
320162505
Phone
781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Planned sale Director sold 8,000 shares at $14.21 ($113,716)
  4. 4 Planned sale Chief Executive Officer sold 32,375 shares at $24.24 ($784,776)
  5. 4 Planned sale Head of R&D, CMO sold 65,515 shares at an average $18.07 ($1,183,643)
  6. 4 Open-market sale Chief Financial Officer sold 1,177 shares at $18.99 ($22,351)
  7. 4 Open-market sale Chief Executive Officer sold 6,847 shares at $18.99 ($130,025)
  8. 4 Open-market sale Chief Executive Officer sold 17,159 shares at $21.03 ($360,819)
  9. 4 Open-market sale Chief Financial Officer sold 3,410 shares at $21.03 ($71,705)
  10. 4 Open-market sale Chief Executive Officer sold 7,412 shares at $20.62 ($152,835)
  11. 4 Open-market sale Chief Financial Officer sold 2,082 shares at $20.62 ($42,931)
  12. 4 Grant or award Director acquired 24,000 shares (grant or award)
  13. 4 Grant or award Director acquired 24,000 shares (grant or award)
  14. 4 Grant or award Head of R&D, CMO acquired 60,000 shares (grant or award)
  15. 4 Grant or award Director acquired 48,000 shares (grant or award)
  16. 4 Grant or award Director acquired 24,000 shares (grant or award)
  17. 4 Grant or award Director acquired 24,000 shares (grant or award)
  18. 4 Grant or award Director acquired 24,000 shares (grant or award)
  19. 4 Gift Chief Financial Officer gave 1,224 shares (gift)
  20. 4 Planned sale Chief Executive Officer sold 157,307 shares at $16.41 ($2,582,021)

Page 1 of 13 · 259 filings